Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Feb;51(2):787-90.
doi: 10.1128/AAC.00673-06. Epub 2006 Nov 20.

Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults

J Keirns  1 , T Sawamoto, M Holum, D Buell, W Wisemandle, A Alak
Affiliations
Randomized Controlled Trial

Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults

J Keirns et al. Antimicrob Agents Chemother. 2007 Feb.

Abstract

We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Plasma concentrations (arithmetic means ± standard deviations) of voriconazole over 24 h (2 doses) on days 4 and 24 (A) and of micafungin over 24 h on days 20 and 24 (B).
See this image and copyright information in PMC

References

    1. Astellas Pharma US, Inc. April 2005. Mycamine (micafungin sodium) for injection: full U.S. prescribing information. Astellas Pharma US, Inc., Deerfield, IL.
    1. Dowell, J. A., J. Schranz, A. Baruch, and G. Foster. 2005. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45:1373-1382. - PubMed
    1. Hatano, K., Y. Morishita, T. Nakai, and F. Ikeda. 2002. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. 55:219-222. - PubMed
    1. Ikeda, F., Y. Wakai, S. Matsumoto, K. Maki, E. Watabe, S. Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618. - PMC - PubMed
    1. Maesaki, S., M. Hossain, Y. Miyazaki, K. Tomono, T. Tashiro, and S. Kohno. 2000. Efficacy of FK463, a (1,3)-β-d-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother. 44:1728-1730. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources